Company Profile
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Latest News
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.ono-pharma.com |
| Audit Risk | 1 |
| Board Risk | 4 |
| Overall Risk | 2 |
| Market Cap | 1.15T |
| Trailing P/E | 16.45 |
| Forward P/E | 14.42 |
| Dividend Rate | 80 |
| Dividend Yield | 3.29% |
| Trailing Annual Div. Rate | 80 |
| Trailing Annual Div. Yield | 3.29% |
| Trailing EPS | 148.29 |
| Forward EPS | 169.15 |
| Book Value | 1,810.41 |
| Price-to-Book | 1.35 |
| Enterprise-to-Revenue | 2.01 |
| Enterprise-to-EBITDA | 7.68 |
| Ex-Dividend Date | 09/29/2026 |
| Earnings Date | 07/31/2026 |
| Earnings Call Date | |
| Revenue Average | 112.15B |
| Revenue Low | 104.30B |
| Revenue High | 119.19B |